Letter in response to Cole-Hunter et al., 2023: What does “Parkinson’s disease mortality” mean?

Related Articles:

• Letter in response to Cole-Hunter et al., 2023: What does "Parkinson's disease mortality" mean? March 17, 2023 Environ Int. 2023 Mar;173:107852. doi: 10.1016/j.envint.2023.107852. Epub 2023 Mar 15.NO ABSTRACTPMID:36931780 | DOI:10.1016/j.envint.2023.107852
• Letter in response to Cole-Hunter et al., 2023: What does "Parkinson's disease mortality" mean? March 17, 2023 Environ Int. 2023 Mar;173:107852. doi: 10.1016/j.envint.2023.107852. Epub 2023 Mar 15.NO ABSTRACTPMID:36931780 | DOI:10.1016/j.envint.2023.107852
• Letter in response to Cole-Hunter et al., 2023: What does "Parkinson's disease mortality" mean? March 17, 2023 Environ Int. 2023 Mar;173:107852. doi: 10.1016/j.envint.2023.107852. Epub 2023 Mar 15.NO ABSTRACTPMID:36931780 | DOI:10.1016/j.envint.2023.107852
• Letter in response to Cole-Hunter et al., 2023: What does "Parkinson's disease mortality" mean? March 17, 2023 Environ Int. 2023 Mar;173:107852. doi: 10.1016/j.envint.2023.107852. Epub 2023 Mar 15.NO ABSTRACTPMID:36931780 | DOI:10.1016/j.envint.2023.107852
• The road ahead: 2022 January 20, 2022 # # # # The first post at the start of each year on the SoPD website tries to provide an overview of where things are in the search for ‘disease modifying’ therapies for Parkinson’s.  It is an exercise in managing expectations as well as discussing what research events are scheduled for the next year so that we can keep…
• GREG GUTFELD: GOP must bring sanity back to government November 11, 2022 Happy Thursday, everybody. So am I the only guy who's been in a great mood since the midterms? I'd like to thank Dr. Siegel for that. But also I'm a silver linings guy. Seriously, right now I'm wearing a thong made of pure silver. It was a Christmas gift from William Devane. Now, you know it's in my safe. But…
• Reply to Rumrich and colleagues (What does "Parkinson's disease mortality" mean?) March 17, 2023 Environ Int. 2023 Mar;173:107853. doi: 10.1016/j.envint.2023.107853. Epub 2023 Mar 15.NO ABSTRACTPMID:36931779 | DOI:10.1016/j.envint.2023.107853
• Reply to Rumrich and colleagues (What does "Parkinson's disease mortality" mean?) March 17, 2023 Environ Int. 2023 Mar;173:107853. doi: 10.1016/j.envint.2023.107853. Epub 2023 Mar 15.NO ABSTRACTPMID:36931779 | DOI:10.1016/j.envint.2023.107853
• Reply to Rumrich and colleagues (What does "Parkinson's disease mortality" mean?) March 17, 2023 Environ Int. 2023 Mar;173:107853. doi: 10.1016/j.envint.2023.107853. Epub 2023 Mar 15.NO ABSTRACTPMID:36931779 | DOI:10.1016/j.envint.2023.107853
• Reply to Rumrich and colleagues (What does "Parkinson's disease mortality" mean?) March 17, 2023 Environ Int. 2023 Mar;173:107853. doi: 10.1016/j.envint.2023.107853. Epub 2023 Mar 15.NO ABSTRACTPMID:36931779 | DOI:10.1016/j.envint.2023.107853
• Reply to Rumrich and colleagues (What does "Parkinson's disease mortality" mean?) March 17, 2023 Environ Int. 2023 Mar;173:107853. doi: 10.1016/j.envint.2023.107853. Epub 2023 Mar 15.NO ABSTRACTPMID:36931779 | DOI:10.1016/j.envint.2023.107853
• Allan Cole on Advocacy, Education, and Living Well with Parkinson’s January 27, 2021 Allan Cole was diagnosed with Young-Onset Parkinson’s Disease (YOPD) in 2016, at age 48. Since then, he has devoted significant time and energy to raising awareness, providing education, fundraising, and writing about his own experiences of living with Parkinson’s. He and a friend also created PD Wise, a hub for sharing personal stories, experiences, and wisdom gained from their journeys…
• The road ahead: 2021 January 25, 2021 # # # # At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the year to come, so that we can keep an eye out for them. Obviously, where 2021 will end actually is unpredictable, but an outline of what is scheduled…
• Subcortical infarction in a young adult with Hunter syndrome February 7, 2022 Brain Dev. 2022 Feb 3:S0387-7604(22)00005-5. doi: 10.1016/j.braindev.2022.01.003. Online ahead of print.ABSTRACTINTRODUCTION: Hunter syndrome (mucopolysaccharidosis type II, MPS II) is an X-linked lysosomal storage disease caused by deficiency of iduronate-2-sulfatase. Recently, stroke caused by embolization with Hunter syndrome has been reported. Here, we report the case of a 23-year-old Japanese man with Hunter syndrome who developed subcortical infarction by the mechanism…
• Subcortical infarction in a young adult with Hunter syndrome February 7, 2022 Brain Dev. 2022 Feb 3:S0387-7604(22)00005-5. doi: 10.1016/j.braindev.2022.01.003. Online ahead of print.ABSTRACTINTRODUCTION: Hunter syndrome (mucopolysaccharidosis type II, MPS II) is an X-linked lysosomal storage disease caused by deficiency of iduronate-2-sulfatase. Recently, stroke caused by embolization with Hunter syndrome has been reported. Here, we report the case of a 23-year-old Japanese man with Hunter syndrome who developed subcortical infarction by the mechanism…
• Subcortical infarction in a young adult with Hunter syndrome February 7, 2022 Brain Dev. 2022 Feb 3:S0387-7604(22)00005-5. doi: 10.1016/j.braindev.2022.01.003. Online ahead of print.ABSTRACTINTRODUCTION: Hunter syndrome (mucopolysaccharidosis type II, MPS II) is an X-linked lysosomal storage disease caused by deficiency of iduronate-2-sulfatase. Recently, stroke caused by embolization with Hunter syndrome has been reported. Here, we report the case of a 23-year-old Japanese man with Hunter syndrome who developed subcortical infarction by the mechanism…
• Subcortical infarction in a young adult with Hunter syndrome February 7, 2022 Brain Dev. 2022 Feb 3:S0387-7604(22)00005-5. doi: 10.1016/j.braindev.2022.01.003. Online ahead of print.ABSTRACTINTRODUCTION: Hunter syndrome (mucopolysaccharidosis type II, MPS II) is an X-linked lysosomal storage disease caused by deficiency of iduronate-2-sulfatase. Recently, stroke caused by embolization with Hunter syndrome has been reported. Here, we report the case of a 23-year-old Japanese man with Hunter syndrome who developed subcortical infarction by the mechanism…
• Subcortical infarction in a young adult with Hunter syndrome February 7, 2022 Brain Dev. 2022 Feb 3:S0387-7604(22)00005-5. doi: 10.1016/j.braindev.2022.01.003. Online ahead of print.ABSTRACTINTRODUCTION: Hunter syndrome (mucopolysaccharidosis type II, MPS II) is an X-linked lysosomal storage disease caused by deficiency of iduronate-2-sulfatase. Recently, stroke caused by embolization with Hunter syndrome has been reported. Here, we report the case of a 23-year-old Japanese man with Hunter syndrome who developed subcortical infarction by the mechanism…
• The Aging Immune System and Parkinson’s October 10, 2022 “Come grow old with me. The best is yet to be.” William Wordsworth “As long as I am breathing, in my eyes, I am just beginning.” Criss Jami Introduction: Recently, an exciting and in-depth review article about inflammation and the immune system and their dysfunction in the pathway of Parkinson’s was published. The citation for this paper is as follows:…
• Year in review: 2021 December 31, 2021 # # # # As with the preceding year, 2021 proved to be challenging due to the continuing COVID-19 pandemic (and it is not over yet). Vaccines were rolled out with remarkable speed, but equally new variants of the virus popped up and have kept Governments and health regulatory bodies on their toes. An amazing feature of the last two…
• Repurposing bumetanide for Alzheimer’s October 15, 2021 # # # # Bumetanide (Bumex) is a diuretic drug (a medication that removes water, by increasing the production of urine). It is used to treat swelling caused by heart failure or liver or kidney disease. It is a widely used drug that has been well characterised in clinical use. Recently researchers conducted a screening study to identify clinically available…
• Long-term exposure to residential greenness and neurodegenerative disease mortality among older adults: a 13-year follow-up cohort study May 7, 2022 Environ Health. 2022 May 7;21(1):49. doi: 10.1186/s12940-022-00863-x.ABSTRACTBACKGROUND: Living in greener areas is associated with slower cognitive decline and reduced dementia risk among older adults, but the evidence with neurodegenerative disease mortality is scarce. We studied the association between residential surrounding greenness and neurodegenerative disease mortality in older adults.METHODS: We used data from the 2001 Belgian census linked to mortality register…